Clinical trial
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT04165070
Study timeline
Study start (actual)2019-12-19Date precision: day
Registry last updated2026-08-25
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
PembrolizumabBIOLOGICAL
CarboplatinDRUG · verified · RxNorm: carboplatin
PaclitaxelDRUG · verified · RxNorm: paclitaxel
PemetrexedDRUG · verified · RxNorm: pemetrexed
VibostolimabBIOLOGICAL
BoserolimabBIOLOGICAL
MK-4830BIOLOGICAL
MK-0482BIOLOGICAL
Ifinatamab Deruxtecan (I-DXd)BIOLOGICAL
HER3-DXdBIOLOGICAL
Sponsors & collaborators
Merck Sharp & Dohme LLClead sponsor
Daiichi Sankyocollaborator
Mapped research locations
BostonMassachusetts, United States2SeoulSouth Korea2New YorkNew York, United States1HoustonTexas, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1San FranciscoCalifornia, United States1MadridSpain1ClevelandOhio, United States1ColumbusOhio, United States1Washington D.C.District of Columbia, United States1MilanItaly1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04165070 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.